MUMBAI, India, June 26 -- Intellectual Property India has published a patent application (202617032662 A) filed by Biocryst Pharmaceuticals, Inc. on March 18, 2026, for Tricyclic Heteroaromatic Inhibitors Of Klk5.
Inventors include Kotian, Pravin, L.; Babu, Yarlagadda, S.; Zhang, Weihe; Liu, Yong; Lv, Wei; Juarez, Luis; Spaulding, Andrew, E.; Dang, Zhao; and Raman, Krishnan.
The application for the patent was published on June 19, 2026, under issue no. 25/2026.
Abstract: Disclosed are tricyclic heteroaromatic compounds of formulae (I) and (II), and pharmaceutically acceptable salts thereof, which are inhibitors of kallikrein-related peptidase 5 (KLK5). Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant KLK5 activity activity, such as Netherton Syndrome. Formulae (I) and (II)
Disclaimer: Curated by HT Syndication.
